Abivax (ABVX) EBITDA (2022 - 2026)

Abivax (ABVX) has reported EBITDA for 5 consecutive years, with -$65.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 32.59% year-over-year to -$65.8 million; the TTM figure through Mar 2026 stood at -$296.3 million (down 57.12% YoY), while the FY2025 annual figure was -$286.5 million, down 54.96% from the prior year.
• EBITDA came in at -$65.8 million for Q1 2026 at Abivax, up from -$83.5 million in the prior quarter.
• The five-year high for EBITDA was -$38.0 million in Q2 2024, with the low at -$137.1 million in Q4 2023.
• Average EBITDA over 5 years is -$67.0 million, with a median of -$55.1 million recorded in 2024.
• Across the five-year window, EBITDA tumbled 107.34% in 2023 and jumped 66.62% in 2024, its largest moves.
• Year by year, EBITDA stood at -$66.1 million in 2022, then slumped by 107.34% to -$137.1 million in 2023, then surged by 66.62% to -$45.8 million in 2024, then slumped by 82.41% to -$83.5 million in 2025, then rose by 21.12% to -$65.8 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$65.8 million, -$83.5 million, and -$94.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.